SCHEMBL4882141

SCHEMBL4882141

Cc1cc(N2CCOCC2)ccc1Nc1ncnc2ccc(I)cc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.57
MAPK1 P28482 2/20 0.57
AHR P35869 1/20 0.57
HTT P42858 1/20 0.57
PI4KB Q9UBF8 1/20 0.48
TTK P33981 5/20 0.46
MAPK14 Q16539 1/20 0.46
TTBK1 Q5TCY1 2/20 0.43
TTBK2 Q6IQ55 2/20 0.43
PRKDC P78527 2/20 0.43
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
ALDH1A1 P00352 2/20 0.42
FLT1 P17948 1/20 0.42
EIF2AK2 P19525 1/20 0.42
EGFR P00533 1/20 0.42
KDR P35968 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4892764 0.85 MAPT (0.54) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4007231 0.84 MAPT (0.78) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4574615 0.82 PI4KB (0.50) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4890249 0.82 CD38 (0.49) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4893003 0.79 MAPT (0.57) MAPTMAPK1AHRHTTPI4KB
SCHEMBL14026144 0.77 MAPT (0.77) MAPTMAPK1AHRHTTPI4KB
Hydrochloric Acid SCHEMBL8871612 0.74 MAPK1 (0.63) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4008515 0.74 MAPT (0.80) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4886099 0.73 MAPT (0.78) MAPTMAPK1AHRHTTPI4KB
SCHEMBL4888050 0.73 MAPT (1.00) MAPTMAPK1AHRHTTPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPT 2064/4885MAPK1 1945/4885AHR 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.